Oxindole Spiro Derivatives for Vasopressin V1b Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds for treating vasopressin-related disorders lack high affinity and selectivity for the vasopressin V1b receptor, along with desirable properties such as metabolic stability, low cytochrome P450 inhibition, suitable solubility, and favorable pharmacokinetics, while also minimizing hERG channel blockade.
Innovation Solution
Development of novel substituted oxindole derivatives with specific ring structures and substituents that enhance binding affinity and selectivity for the vasopressin V1b receptor, combined with improved metabolic stability and reduced interaction with cytochrome P450 enzymes and hERG channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds are used for treating vasopressin-related disorders, then they provide basic therapeutic effect, but they lack high affinity and selectivity for the vasopressin V1b receptor
Solution Approach 1:
The patent introduces specific local structural features at defined positions of the oxindole core. Position 3 carries a nitrogen-bound spiro substituent with specific ring sizes (5-7 membered), position 1 has arylsulfonyl groups with specific substituents, and position 2 has heteroaryl groups. These localized structural modifications at specific positions enhance V1b receptor affinity and selectivity without compromising other desirable properties.
Solution Approach 2:
The patent systematically varies key molecular parameters including the size of spiro rings (5, 6, or 7 membered), the nature of substituents at positions 1, 2, and 3, and the overall molecular weight and hydrophobicity. These parameter optimizations lead to compounds with improved binding affinity (low nanomolar Ki values) and enhanced selectivity profile (Ki(V1a)/Ki(V1b) > 10, Ki(V2)/Ki(V1b) > 10).
2Force
If compounds are designed for high receptor affinity, then binding strength increases, but metabolic stability and cytochrome P450 inhibition profile may worsen
Solution Approach 1:
The patent introduces metabolically stable local structures such as spiro-cyclic systems and specific heteroaryl groups that resist enzymatic degradation. These localized structural features provide both high receptor affinity and metabolic stability simultaneously, avoiding the trade-off between binding strength and metabolic stability.
3Reliability
If compounds show high V1b receptor selectivity, then therapeutic specificity improves, but other pharmacokinetic properties such as solubility and hERG channel blockade may be affected
Solution Approach 1:
The patent designs compounds where the same structural features that provide high V1b selectivity (specific spiro substituents, heteroaryl groups, and substituent patterns) also inherently reduce hERG channel affinity. The molecular characteristics optimized for V1b selectivity naturally confer reduced cardiac risk, converting the selectivity requirement into a beneficial dual effect.
Data Source
AI summary
The present invention relates to novel substituted oxindole derivatives of the formula Iwherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent R6 and optionally one substituent R7; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R8; X1, X2, X3 and X4, independently of each other, are selected from —CH2—, —O—, —S(O)c—, —NH—, —C(O)—, —CH2CH2—, —CH2O—, —OCH2—, —S(O)cCH2—, —CH2S(O)c—, CH2NH—, —NHCH2—, —CH2C(O)— and C(O)CH2—;X5 is NH, CH2 or O; and wherein c, R1, R2, (R3)a, (R4)b, R5, R6, R7, and R8 are as defined in the claims.The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.